University of Southampton
southampton.ac.ukLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
120
Active
22
Phase 3
5
Total enrollment
2,257,447
Pipeline matrix
Showing 11 of 11 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Flucloxacillin Only Product in Oral Dose Form | — | — | — | — | — | 1 | |
| Mitomycin c | — | — | — | — | — | 1 | |
| ifosfamide | — | — | — | — | — | 2 | |
| rituximab | — | — | — | — | — | 2 | |
| Carboplatin | — | — | — | — | — | 2 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| Etoposide | — | — | — | — | — | 1 | |
| BMS-986504 | — | — | — | — | — | 1 | |
| Trastuzumab deruxtecan | — | — | — | — | — | 1 | |
| Bordetella pertussis B1917 | — | — | — | — | — | 2 | |
| Azithromycin Pill | — | — | — | — | — | 1 |
Next readouts
- 2026-03-31
- 2026-05
- 2026-05-30
- 2026-12-01
- 2027-07
- 2028-09
Top conditions
- Stroke6
- Asthma5
- Parkinson Disease4
- Malnutrition3
- Meningitis, Bacterial3
- Chronic Pain3
- Chronic Obstructive Pulmonary Disease3
- Colorectal Cancer3
Frequently asked questions about University of Southampton
- How many clinical trials does University of Southampton have on ClinicalTrials.gov?
- University of Southampton is listed as the lead sponsor on 120 clinical trials in ClinicalTrials.gov, 22 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Southampton's trials are in Phase 3?
- 5 of University of Southampton's trials are in Phase 3, spread across 11 active drug programs.
- What therapeutic areas does University of Southampton focus on?
- University of Southampton's most-studied conditions on ClinicalTrials.gov are Stroke, Asthma, Parkinson Disease, Malnutrition, Meningitis, Bacterial.
- When are University of Southampton's next clinical trial readouts?
- University of Southampton has 6 upcoming primary-completion readouts tracked here; the soonest is “Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer”, expected around 2026-03-31.